无创性指标对肝硬化临床终点事件的预测  

Value of noninvasive indicators in predicting clinical outcome events of liver cirrhosis

作　　者：徐铭益[1] 徐梓馨 XU Mingyi;XU Zixin(Department of Gastroenterology, The First People’s Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200080, China)

机构地区：[1]上海交通大学附属第一人民医院消化科,上海200080

出　　处：《临床肝胆病杂志》2020年第9期1941-1946,共6页Journal of Clinical Hepatology

摘　　要：目前关于肝硬化的无创诊断指标的研究越来越多,但其与肝硬化临床终点事件的关系以及预测价值尚未有统一。针对血清学指标、血清诊断模型、肝硬度值(LSM)等无创性指标在肝硬化临床终点事件预测中的价值进行归纳。血清指标(PLT、FibroTest等)结合LSM的无创诊断方法可评估肝纤维化分期,也能较好的预测肝硬化终点事件及远期预后,已被写入国内外指南中广泛应用于临床。采用新的组合(比如LSM联合血清指标或诊断模型)或逐步计算法可展现出改良的希望,从而实现患者的个体化动态临床管理,减少或避免肝硬化临床终点事件的发生,使肝硬化患者最大获益。At present,more and more studies have been conducted on noninvasive diagnostic indicators for liver cirrhosis,but no consensus has been reached on the association of noninvasive diagnostic indicators with clinical outcome events and their predictive value.This article summarizes the value of noninvasive indicators,including serological markers,serum diagnostic models,and liver stiffness measurement(LSM),in predicting the clinical outcome events of liver cirrhosis.The noninvasive diagnostic method of serological markers(such as platelet count and FibroTest)combined with LSM can assess the stage of liver fibrosis and predict the outcome events and long-term prognosis of liver cirrhosis,and thus it has been included in Chinese and global guidelines and has been widely used in clinical practice.The use of new combinations(such as LSM combined with serological markers or diagnostic models)or a step-by-step calculation method shows the hope of modification to realize individualized dynamic clinical management of patients,reduce or avoid the occurrence of clinical outcome events of liver cirrhosis,and bring maximum benefit to patients with liver cirrhosis.

关 键 词：肝硬化 生物标记 弹性成像技术 

分 类 号：R575.2[医药卫生—消化系统]